Commentary on the "Evidence- and Consensus-Based (S3) Guidelines for the Treatment of Actinic Keratosis" Published by the International League of Dermatological Societies in Cooperation with the European Dermatology Forum

Skin Pharmacol Physiol. 2018;31(3):144-146. doi: 10.1159/000486687. Epub 2018 Apr 3.

Abstract

In 2015, the International League of Dermatological Societies and the European Dermatology Forum published a guideline for the treatment of actinic keratosis, which is classified as an evidence- and consensus-based S3 guideline. From the point of view of the GD Task Force "Licht.Hautkrebs.Prävention," an interdisciplinary expert panel of the Society for Dermopharmacy for the prevention and treatment of skin cancer, this guideline reveals strengths and weaknesses but, in summary, does not meet the claim for an evidence- and consensus-based S3 guideline.

Keywords: Actinic keratosis; Evidence-based medicine; International guideline; National guideline; Patient groups; Society for Dermopharmacy; Treatment recommendations.

MeSH terms

  • Consensus
  • Dermatology / methods
  • Evidence-Based Medicine
  • Humans
  • Keratosis, Actinic / therapy*
  • Practice Guidelines as Topic*
  • Skin Neoplasms / prevention & control*
  • Skin Neoplasms / therapy